-
Income Statement
-
Balance Sheet
-
Cashflow Statement
-
Profitability
-
Ratios
AbbVie Income Statement
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Revenue |
|
$45.80 B | $56.20 B | $58.05 B | $54.32 B | $56.33 B |
| Cost of Revenue |
|
$15.39 B | $17.45 B | $17.41 B | $20.42 B | $16.90 B |
| Gross Profit |
|
$30.42 B | $38.75 B | $40.64 B | $33.90 B | $39.43 B |
| Research & Development |
|
$6.56 B | $7.08 B | $6.51 B | $8.45 B | $12.79 B |
| Selling,General & Administrative |
|
$11.30 B | $12.35 B | $15.26 B | $12.87 B | $14.75 B |
| Operating Expense |
|
$17.86 B | $19.87 B | $21.83 B | $21.15 B | $30.29 B |
| Operating Income |
|
$11.36 B | $17.92 B | $18.12 B | $12.76 B | $9.14 B |
| Net Income |
|
$4.62 B | $11.54 B | $11.84 B | $4.86 B | $4.28 B |
AbbVie Balance Sheet
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Cash and Cash Equivalents |
|
$8.48 B | $9.83 B | $9.23 B | $12.82 B | $5.56 B |
| Inventories |
|
$3.31 B | $3.13 B | $3.58 B | $4.10 B | $4.18 B |
| Total Current Assets |
|
$24.17 B | $27.93 B | $28.46 B | $33.00 B | $25.58 B |
| Property,Plant and Equipment |
|
$5.25 B | $5.11 B | $4.94 B | $4.99 B | $5.13 B |
| Goodwill |
|
$33.12 B | $32.38 B | $32.16 B | $32.29 B | $34.96 B |
| Total Assets |
|
$150.57 B | $146.53 B | $138.81 B | $134.71 B | $135.16 B |
| Total Liabilities |
|
$137.47 B | $131.09 B | $121.52 B | $124.31 B | $131.80 B |
| Retained Earnings |
|
$1.06 B | $3.13 B | $4.78 B | -$1.00 B | -$7.90 B |
| Total Shareholder Equity |
|
$13.08 B | $15.41 B | $17.25 B | $10.36 B | $3.33 B |
| Common Stock |
|
$18.00 M | $18.00 M | $18.00 M | $18.00 M | $18.00 M |
AbbVie Cash flow
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Depreciation & Amortization |
|
$6.47 B | $8.52 B | $8.47 B | $8.70 B | $8.39 B |
| Dividends Payout |
|
-$7.72 B | -$9.26 B | -$10.04 B | -$10.54 B | -$11.03 B |
| Capital Expenditures (Capex) |
|
-$798.00 M | -$787.00 M | -$695.00 M | -$777.00 M | - |
| Free Cash Flow (FCF) |
|
$16.79 B | $21.99 B | $24.25 B | $22.06 B | $18.81 B |
AbbVie Profitability
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Gross Profit |
|
$30.42 B | $38.75 B | $40.64 B | $33.90 B | $39.43 B |
| Gross Profit Margin (%) |
|
66.41% | 68.96% | 70.00% | 62.42% | 69.99% |
| Operating Income |
|
$11.36 B | $17.92 B | $18.12 B | $12.76 B | $9.14 B |
| Operating Income Margin (%) |
|
24.81% | 31.89% | 31.21% | 23.49% | 16.22% |
| Net Income |
|
$4.62 B | $11.54 B | $11.84 B | $4.86 B | $4.28 B |
| Net Income Margin (%) |
|
10.08% | 20.54% | 20.39% | 8.95% | 7.59% |
| EBITDA |
|
$21.15 B | $28.28 B | $31.42 B | $17.31 B | $14.91 B |
| EBITDA Margin (%) |
|
46.17% | 50.32% | 54.13% | 31.86% | 26.47% |
AbbVie Ratios
| Chart | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|
| Return on Equity (ROE) |
|
35.30% | 74.91% | 68.60% | 46.94% | 128.66% |
| Return on Assets (ROA) |
|
3.07% | 7.88% | 8.53% | 3.61% | 3.17% |
| Debt to Equity |
|
658.12% | 497.69% | 366.70% | 573.21% | 2,019.37% |
| Debt to total asset |
|
57.16% | 52.33% | 45.58% | 44.08% | 49.68% |
| Enterprise value to revenue |
|
5.59 | 5.46 | 5.86 | 5.90 | 6.66 |
| Enterprise value to EBITDA |
|
12.12 | 10.84 | 10.83 | 18.52 | 25.17 |
| Enterprise value |
|
$256.23 B | $306.60 B | $340.28 B | $320.56 B | $375.31 B |
| Cash to Debt |
|
20.44% | 29.70% | 39.42% | 38.46% | 28.01% |
| Tax Rate (%) |
|
36.02% | 11.09% | 12.11% | 22.03% | -15.34% |
| Payout Ratio |
|
167.16% | 80.24% | 84.85% | 216.72% | 257.71% |
